Home › Bell Radar › IAM

IAMIambic Therapeutics

US ExchangeHealth Care2026-10-15

Clinical-stage biotech integrating proprietary large-scale AI with automated chemistry/biology experimentation for drug discovery.

$16IPO price
$150MRaised
$18.91Day-1 close
18.19%Day-1 return
Clinical-stage biotech integrating proprietary large-scale AI with automated chemistry/biology experimentation for drug discovery.
Company description (source: StockAnalysis)

Iambic Therapeutics is a technology and clinical-stage life sciences company pursuing a fundamental shift in the biopharmaceutical industry. Our mission is to make better technology for better medicines. We do this by integrating leading proprietary, large-scale artificial intelligence (AI) with automated, scalable chemistry and biology experimentation. We call this approach molecular superintelligence. Instead of treating each stage of drug discovery as a distinct technological challenge, we have developed a unified, intelligent platform desig...

医疗健康人工智能创新药
51CFO read: CFO must master AI-pharma monetization, R&D capitalization standards, and biotech IPO financial modeling.
Management details per the SEC prospectus.
Does your company need this kind of CFO?

51CFO matches you with Western CFOs who have each run a full US IPO — plus other C-level talent. First shortlist within 48 hours; free 30-minute listing-readiness read.

Talk to us